Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Impulse Control Disorder
Conditions
Impulse Control Disorder
Trial Timeline
Nov 1, 2012 → Dec 1, 2014
NCT ID
NCT01683253About Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists
Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists is a approved stage product being developed by Sandoz Group for Impulse Control Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01683253. Target conditions include Impulse Control Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01683253 | Approved | Completed |
Competing Products
1 competing product in Impulse Control Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sertraline | Pfizer | Approved | 84 |